BACKGROUND: The English arm of the UK Bowel Cancer Screening Pilot study recently concluded its third round. The primary aim was to assess the impact of faecal occult blood test (FOBT) screening on the detection of symptomatic (non-screen-detected) cancers within the target age group (50-69 years). The secondary aim was to assess differences between screened and non-screened cohorts in Dukes' classification at diagnosis. METHODS: This population-based study utilized retrospective analysis of existing validated colorectal cancer (CRC) data over 5 years (April 2000 to March 2005), encompassing rounds one and two of screening. RESULTS: There was a 23 per cent (P = 0.011) reduction in the diagnosis of over the 5 years. Presentations with symptomatic cancer reduced by 49 per cent (P = 0.049), with a proportionate (2.6-fold) rise in the detection of screened (asymptomatic) malignancy. Cancers were diagnosed at an earlier stage in the screened population, with significantly more Dukes' A tumours than in the non-screen-detected cohort (P < 0.001) and an estimated odds ratio of 0.27 (95 per cent confidence interval 0.08 to 0.91) (P = 0.035) for Dukes' 'D' cancers. CONCLUSION: FOBT screening resulted in a significant reduction in the number of symptomatic cancers detected within the target age group. Tumours detected by screening were diagnosed at an earlier pathological stage.
BACKGROUND: The English arm of the UK Bowel Cancer Screening Pilot study recently concluded its third round. The primary aim was to assess the impact of faecal occult blood test (FOBT) screening on the detection of symptomatic (non-screen-detected) cancers within the target age group (50-69 years). The secondary aim was to assess differences between screened and non-screened cohorts in Dukes' classification at diagnosis. METHODS: This population-based study utilized retrospective analysis of existing validated colorectal cancer (CRC) data over 5 years (April 2000 to March 2005), encompassing rounds one and two of screening. RESULTS: There was a 23 per cent (P = 0.011) reduction in the diagnosis of over the 5 years. Presentations with symptomatic cancer reduced by 49 per cent (P = 0.049), with a proportionate (2.6-fold) rise in the detection of screened (asymptomatic) malignancy. Cancers were diagnosed at an earlier stage in the screened population, with significantly more Dukes' A tumours than in the non-screen-detected cohort (P < 0.001) and an estimated odds ratio of 0.27 (95 per cent confidence interval 0.08 to 0.91) (P = 0.035) for Dukes' 'D' cancers. CONCLUSION: FOBT screening resulted in a significant reduction in the number of symptomatic cancers detected within the target age group. Tumours detected by screening were diagnosed at an earlier pathological stage.
Authors: Sofia M McCulloch; Imran Aziz; Annikka V Polster; Andreas-Bernd Pischel; Henrik Stålsmeden; Morteza Shafazand; Mattias Block; Gunnar Byröd; Björn Lindkvist; Hans Törnblom; Börje Jonefjäll; Magnus Simren Journal: United European Gastroenterol J Date: 2019-11-06 Impact factor: 4.623
Authors: B Andreoni; C Crosta; A Sonzogni; Me Pirola; A Pavan; L Bisanti; C Senore; R Sassatelli; R Sguinzi; E Bertani; Pp Bianchi; Ac Chiappa Journal: Ecancermedicalscience Date: 2009-05-12
Authors: Sietze T van Turenhout; Jochim S Terhaar sive Droste; Gerrit A Meijer; Ad A Masclée; Chris J J Mulder Journal: BMC Cancer Date: 2012-01-26 Impact factor: 4.430
Authors: William Hamilton; Robert Lancashire; Debbie Sharp; Tim J Peters; Kk Cheng; Tom Marshall Journal: BMC Med Date: 2009-04-17 Impact factor: 8.775
Authors: S T Ward; C J Weston; E Hepburn; S Damery; R K Hejmadi; D G Morton; G Middleton; T Ismail; D H Adams Journal: Eur J Surg Oncol Date: 2013-11-06 Impact factor: 4.424